Trial Outcomes & Findings for Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis (NCT NCT02471144)

NCT ID: NCT02471144

Last Updated: 2023-10-11

Results Overview

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 162 participants
• Primary outcome timeframe: 12 weeks
• Results posted on: 2023-10-11

Participant Flow

This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric patients aged 6 years to less than 18 years with severe chronic plaque psoriasis. A total of 187 patients were screened, of which 162 were randomized.

Participant milestones

Measure	AIN457 Low Dose (Induction Period) Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose (Induction Period) Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo (Induction Period) Patients received matching placebo to secukinumab at each dosing	Etanercept Comparator (Induction Period) Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	AIN457 Low Dose (Maintenance Period) Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose (Maintenance Period) Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo-AIN457 Low Dose (Maintenance Period) Patients received placebo during Induction and if they were PASI 75 non-responders at Week 12 switched to AIN457 Low Dose for the remainder of the study	Placebo-AIN457 High Dose (Maintenance Period Patients received placebo during Induction and if they were PASI 75 non-responders at Week 12 switched to AIN457 High Dose for the remainder of the study	Etanercept Comparator (Maintenance Period) Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Any AIN457 Low Dose (Extension Period) Includes patients from the AIN457 Low Dose and from the Placebo-AIN457 Low Dose groups	Any AIN457 High Dose (Extension Period) Includes patients from the AIN457 High Dose and from the Placebo-AIN457 High Dose groups
Induction Period (Up to Week 12) STARTED	40	40	41	41	0	0	0	0	0	0	0
Induction Period (Up to Week 12) COMPLETED	39	38	39	40	0	0	0	0	0	0	0
Induction Period (Up to Week 12) NOT COMPLETED	1	2	2	1	0	0	0	0	0	0	0
Maintenance Period (Week 12 to Week 52) STARTED	0	0	0	0	39	38	16	18	40	0	0
Maintenance Period (Week 12 to Week 52) COMPLETED	0	0	0	0	38	37	15	16	34	0	0
Maintenance Period (Week 12 to Week 52) NOT COMPLETED	0	0	0	0	1	1	1	2	6	0	0
Extension Period (Week 52 to Week 236) STARTED	0	0	0	0	0	0	0	0	0	53	53
Extension Period (Week 52 to Week 236) COMPLETED	0	0	0	0	0	0	0	0	0	39	43
Extension Period (Week 52 to Week 236) NOT COMPLETED	0	0	0	0	0	0	0	0	0	14	10

Reasons for withdrawal

Measure	AIN457 Low Dose (Induction Period) Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose (Induction Period) Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo (Induction Period) Patients received matching placebo to secukinumab at each dosing	Etanercept Comparator (Induction Period) Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	AIN457 Low Dose (Maintenance Period) Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose (Maintenance Period) Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo-AIN457 Low Dose (Maintenance Period) Patients received placebo during Induction and if they were PASI 75 non-responders at Week 12 switched to AIN457 Low Dose for the remainder of the study	Placebo-AIN457 High Dose (Maintenance Period Patients received placebo during Induction and if they were PASI 75 non-responders at Week 12 switched to AIN457 High Dose for the remainder of the study	Etanercept Comparator (Maintenance Period) Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Any AIN457 Low Dose (Extension Period) Includes patients from the AIN457 Low Dose and from the Placebo-AIN457 Low Dose groups	Any AIN457 High Dose (Extension Period) Includes patients from the AIN457 High Dose and from the Placebo-AIN457 High Dose groups
Induction Period (Up to Week 12) Adverse Event	0	1	1	0	0	0	0	0	0	0	0
Induction Period (Up to Week 12) Lack of Efficacy	0	0	0	1	0	0	0	0	0	0	0
Induction Period (Up to Week 12) Protocol Deviation	0	0	1	0	0	0	0	0	0	0	0
Induction Period (Up to Week 12) Subject/Guardian Decision	1	1	0	0	0	0	0	0	0	0	0
Maintenance Period (Week 12 to Week 52) Adverse Event	0	0	0	0	1	0	1	0	1	0	0
Maintenance Period (Week 12 to Week 52) Lack of Efficacy	0	0	0	0	0	1	0	0	3	0	0
Maintenance Period (Week 12 to Week 52) Pregnancy	0	0	0	0	0	0	0	0	1	0	0
Maintenance Period (Week 12 to Week 52) Protocol Deviation	0	0	0	0	0	0	0	2	1	0	0
Extension Period (Week 52 to Week 236) Lack of Efficacy	0	0	0	0	0	0	0	0	0	6	3
Extension Period (Week 52 to Week 236) Pregnancy	0	0	0	0	0	0	0	0	0	2	0
Extension Period (Week 52 to Week 236) Lost to Follow-up	0	0	0	0	0	0	0	0	0	0	2
Extension Period (Week 52 to Week 236) Adverse Event	0	0	0	0	0	0	0	0	0	2	2
Extension Period (Week 52 to Week 236) Technical problems	0	0	0	0	0	0	0	0	0	1	0
Extension Period (Week 52 to Week 236) Subject/guardian decision	0	0	0	0	0	0	0	0	0	3	3

Baseline Characteristics

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

Baseline characteristics by cohort

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Total n=162 Participants Total of all reporting groups
Age, Continuous	13.7 Years STANDARD_DEVIATION 2.92 • n=5 Participants	13.2 Years STANDARD_DEVIATION 3.21 • n=7 Participants	13.7 Years STANDARD_DEVIATION 3.27 • n=5 Participants	13.5 Years STANDARD_DEVIATION 2.94 • n=4 Participants	13.5 Years STANDARD_DEVIATION 3.06 • n=21 Participants
Age, Customized <12 years	8 Participants n=5 Participants	9 Participants n=7 Participants	10 Participants n=5 Participants	10 Participants n=4 Participants	37 Participants n=21 Participants
Age, Customized >=12 years	32 Participants n=5 Participants	31 Participants n=7 Participants	31 Participants n=5 Participants	31 Participants n=4 Participants	125 Participants n=21 Participants
Sex: Female, Male Female	27 Participants n=5 Participants	23 Participants n=7 Participants	22 Participants n=5 Participants	25 Participants n=4 Participants	97 Participants n=21 Participants
Sex: Female, Male Male	13 Participants n=5 Participants	17 Participants n=7 Participants	19 Participants n=5 Participants	16 Participants n=4 Participants	65 Participants n=21 Participants
Race/Ethnicity, Customized Caucasian	34 Participants n=5 Participants	34 Participants n=7 Participants	36 Participants n=5 Participants	30 Participants n=4 Participants	134 Participants n=21 Participants
Race/Ethnicity, Customized Black	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants
Race/Ethnicity, Customized Asian	1 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants	7 Participants n=21 Participants
Race/Ethnicity, Customized Native American	3 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	8 Participants n=4 Participants	17 Participants n=21 Participants
Race/Ethnicity, Customized Other	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants

PRIMARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a 75% Improvement From Baseline in PASI Score at Week 12	32 Participants	31 Participants	6 Participants	26 Participants	—

PRIMARY outcome

Timeframe: 12 Weeks

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=40 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Who Showed Investigator's Global Assessment (IGA) Mod 2011 Response of 0 or 1 at Week 12	28 Participants	24 Participants	2 Participants	14 Participants	—

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a 90% Improvement From Baseline in PASI Score at Week 12	29 Participants	27 Participants	1 Participants	12 Participants	—

SECONDARY outcome

Timeframe: 12 weeks

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 50 represents the percentage (or number) of patients who have achieved a 50% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12 PASI 50	34 Participants	34 Participants	9 Participants	34 Participants	—
Number and Percentage of Participants Achieving a 50%, 100% Improvement From Baseline in PASI Score at Week 12 PASI 100	12 Participants	11 Participants	0 Participants	7 Participants	—

SECONDARY outcome

Timeframe: Weeks 4, 8

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 4- IGA 0/1	6 Participants	13 Participants	0 Participants	1 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 4- PASI 50	26 Participants	28 Participants	6 Participants	19 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 4- PASI 75	13 Participants	22 Participants	0 Participants	5 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 4- PASI 90	5 Participants	9 Participants	0 Participants	1 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 4- PASI 100	3 Participants	3 Participants	0 Participants	0 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 8- IGA 0/1	21 Participants	18 Participants	0 Participants	6 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 8- PASI 50	32 Participants	32 Participants	11 Participants	30 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 8- PASI 75	27 Participants	26 Participants	1 Participants	15 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 8- PASI 90	20 Participants	20 Participants	0 Participants	4 Participants	—
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 up to Week 12 (Induction) Week 8-PASI 100	9 Participants	7 Participants	0 Participants	2 Participants	—

SECONDARY outcome

Timeframe: Weeks 16, 20, 24, 36, 48 and 52

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema, Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). PASI will be assessed/calculated as per standard procedure. IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=16 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=18 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 36- PASI 50	37 Participants	37 Participants	16 Participants	16 Participants	31 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 36- PASI 75	35 Participants	35 Participants	16 Participants	16 Participants	26 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 36-PASI 90	32 Participants	31 Participants	10 Participants	7 Participants	18 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 36-PASI 100	17 Participants	20 Participants	10 Participants	7 Participants	10 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 48- IGA 0/1	28 Participants	28 Participants	14 Participants	14 Participants	21 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 48-PASI 50	38 Participants	35 Participants	15 Participants	15 Participants	31 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 48- PASI 75	35 Participants	35 Participants	14 Participants	15 Participants	27 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 48- PASI 90	29 Participants	30 Participants	12 Participants	14 Participants	23 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 16- IGA 0/1	32 Participants	28 Participants	5 Participants	8 Participants	19 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 16- PASI 50	37 Participants	35 Participants	11 Participants	16 Participants	30 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 16- PASI 75	36 Participants	32 Participants	5 Participants	11 Participants	26 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 16- PASI 90	33 Participants	30 Participants	4 Participants	7 Participants	16 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 16- PASI 100	19 Participants	14 Participants	0 Participants	1 Participants	8 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 20- IGA 0/1	33 Participants	28 Participants	12 Participants	13 Participants	21 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 20- PASI 50	38 Participants	36 Participants	15 Participants	17 Participants	32 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 20- PASI 75	38 Participants	35 Participants	13 Participants	15 Participants	29 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 20- PASI 90	33 Participants	30 Participants	12 Participants	12 Participants	19 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 20- PASI 100	20 Participants	16 Participants	5 Participants	4 Participants	8 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 24- IGA 0/1	35 Participants	30 Participants	14 Participants	14 Participants	20 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 24- PASI 50	38 Participants	37 Participants	15 Participants	16 Participants	31 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 24- PASI 75	37 Participants	35 Participants	15 Participants	14 Participants	26 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 24- PASI 90	33 Participants	31 Participants	13 Participants	12 Participants	19 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 24- PASI 100	22 Participants	17 Participants	7 Participants	6 Participants	9 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 36- IGA 0/1	32 Participants	29 Participants	14 Participants	14 Participants	21 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 48- PASI 100	16 Participants	18 Participants	10 Participants	8 Participants	12 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 52- 1GA 0/1	29 Participants	30 Participants	14 Participants	13 Participants	23 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 52- PASI 50	39 Participants	37 Participants	15 Participants	17 Participants	32 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 52- PASI 75	35 Participants	35 Participants	14 Participants	17 Participants	28 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 52- PASI 90	30 Participants	32 Participants	13 Participants	14 Participants	21 Participants
Number and Percentage of Participants Achieving a 50%, 75%, 90% or 100% Improvement From Baseline in PASI Score and IGA Mod 2011 Score of 0 or 1 Up to Week 52 (Maintenance) Week 52- PASI 100	16 Participants	19 Participants	10 Participants	10 Participants	9 Participants

SECONDARY outcome

Timeframe: Week 12

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Outcome measures

Measure	AIN457 Low Dose n=39 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=39 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=40 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Change From Baseline in Psoriasis Area & Severity Index (PASI) Score at Week 12	-22.27 Scores on a scale Standard Deviation 8.518	-22.67 Scores on a scale Standard Deviation 11.904	-7.94 Scores on a scale Standard Deviation 9.396	-20.91 Scores on a scale Standard Deviation 10.055	—

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) & Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, upper limbs: 0.2 trunk: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

Outcome measures

Measure	AIN457 Low Dose n=39 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=39 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=16 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=18 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Change From Baseline in Psoriasis Area & Severity Index (PASI) Scores at Week 52	-25.26 Scores on a scale Standard Deviation 7.150	-25.75 Scores on a scale Standard Deviation 8.593	-28.49 Scores on a scale Standard Deviation 7.984	-24.69 Scores on a scale Standard Deviation 5.520	-21.16 Scores on a scale Standard Deviation 11.779

SECONDARY outcome

Timeframe: Week 12

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12 Week 12- IGA Category: Clear	12 Participants	11 Participants	0 Participants	7 Participants	—
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12 Week 12- IGA Category: Almost Clear	14 Participants	13 Participants	2 Participants	7 Participants	—
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12 Week 12- IGA Category: Mild Disease	8 Participants	7 Participants	4 Participants	18 Participants	—
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12 Week 12- IGA Category: Moderate Disease	3 Participants	4 Participants	11 Participants	6 Participants	—
Percentage of Participants in IGA Mod 2011 Score Categories at Week 12 Week 12- IGA Category: Severe Disease	2 Participants	4 Participants	23 Participants	3 Participants	—

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS

IGA: The IGA mod 2011 scale has following different scores for the state of disease: 0: Clear, No signs of psoriasis. 1: Almost clear 2: Mild 3: Moderate 4 : Severe

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=16 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=18 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52 Week 52- IGA Category: Moderate Disease	2 Participants	2 Participants	0 Participants	0 Participants	4 Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52 Week 52- IGA Category: Clear	16 Participants	20 Participants	10 Participants	10 Participants	9 Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52 Week 52- IGA Category: Almost Clear	13 Participants	10 Participants	4 Participants	4 Participants	14 Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52 Week 52- IGA Category: Mild Disease	7 Participants	4 Participants	2 Participants	4 Participants	9 Participants
Percentage of Participants in IGA Mod 2011 Score Categories at Week 52 Week 52- IGA Category: Severe Disease	1 Participants	3 Participants	0 Participants	0 Participants	5 Participants

SECONDARY outcome

Timeframe: Weeks 4, 8, 12

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS.

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction) Week 12	-67.43 percentage change of score Standard Deviation 41.602	-62.5 percentage change of score Standard Deviation 50.08	-18.48 percentage change of score Standard Deviation 80.018	-62.80 percentage change of score Standard Deviation 34.419	—
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction) Week 4	-47.71 percentage change of score Standard Deviation 45.743	-50.71 percentage change of score Standard Deviation 37.003	1.67 percentage change of score Standard Deviation 104.216	-35.13 percentage change of score Standard Deviation 56.832	—
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 12 (Induction) Week 8	-61.60 percentage change of score Standard Deviation 54.371	-66.97 percentage change of score Standard Deviation 32.040	-17.77 percentage change of score Standard Deviation 66.451	-42.73 percentage change of score Standard Deviation 54.026	—

SECONDARY outcome

Timeframe: Weeks 24, 36, 52

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS.

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=16 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=18 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance) Week 36	-79.0 percentage change of score Standard Deviation 31.99	-56.2 percentage change of score Standard Deviation 107.65	-89.5 percentage change of score Standard Deviation 19.11	-69.4 percentage change of score Standard Deviation 46.46	-47.7 percentage change of score Standard Deviation 45.01
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance) Week 24	-73.7 percentage change of score Standard Deviation 55.02	-53.9 percentage change of score Standard Deviation 74.63	40.3 percentage change of score Standard Deviation 477.93	-73.8 percentage change of score Standard Deviation 53.09	-55.0 percentage change of score Standard Deviation 44.98
Percentage Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Score Up to Week 52 (Maintenance) Week 52	-80.9 percentage change of score Standard Deviation 39.38	-58.6 percentage change of score Standard Deviation 77.56	-89.0 percentage change of score Standard Deviation 15.73	-86.0 percentage change of score Standard Deviation 23.19	-53.4 percentage change of score Standard Deviation 56.99

SECONDARY outcome

Timeframe: Weeks 4, 8, 12

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS.

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=41 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction) Week 4	8 Participants	11 Participants	2 Participants	9 Participants	—
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction) Week 8	15 Participants	19 Participants	7 Participants	10 Participants	—
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 12 (Induction) Week 12	17 Participants	19 Participants	6 Participants	15 Participants	—

SECONDARY outcome

Timeframe: Weeks 24, 36, 52

Population: Full Analysis Set: The FAS comprised all patients from the randomized set to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual stratum was different to the assigned stratum in Interactive Response Technology (IRT), the actual stratum was used in analyses. Patients excluded from the randomized set were excluded from the FAS.

The CDLQI measures functional disability of subjects with dermatological disorders who are less than 18 years of age and it has been utilized as a relevant clinical measure in atopic dermatitis, as well as other dermatitis clinical trials. The CDLQI is a simple, validated, self-administered 10-item questionnaire. The instrument contains six functional scales (i.e., symptoms and feeling, leisure, school or holidays, personal relationships, sleep and treatment). The questions are based on the preceding week to permit accurate recall. For the CDLQI, each question will be answered on a 4-point Likert scale scored from 0 to 3. Seven scores will be derived from the CDLQI: the total score of each of the six dimensions as well as the total score over all items. The higher the score, the more quality of life is impaired.

Outcome measures

Measure	AIN457 Low Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=40 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=16 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=18 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=41 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance) Week 24	19 Participants	17 Participants	8 Participants	9 Participants	17 Participants
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance) Week 36	21 Participants	21 Participants	9 Participants	8 Participants	12 Participants
Number and Percentage of Participants Achieving a Children's DLQI Score of 0 or 1 Over Time up to Week 52 (Maintenance) Week 52	20 Participants	22 Participants	8 Participants	11 Participants	16 Participants

SECONDARY outcome

Timeframe: Week 12

Population: No summary statistics were derived for CHAQ, due to the low number of subjects (11) who completed the CHAQ questionnaire: 4 from secukinumab low dose group, 3 from etanercept group, 2 from placebo - secukinumab high dose group and 1 each from secukinumab high dose group and placebo - secukinumab low dose group. At Week 12 analysis visit, 4 patients achieved CHAQ response (2 each from secukinumab low dose and etanercept groups)

The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

Outcome measures

Measure	AIN457 Low Dose n=4 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=2 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=2 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=3 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 12	2 Participants	0 Participants	0 Participants	2 Participants	—

SECONDARY outcome

Timeframe: Week 52

Population: No summary statistics were derived for CHAQ, due to the low number of subjects (11) who completed the CHAQ questionnaire: 4 secukinumab low dose, 1 secukinumab high dose, 3 Etanercept, who were evaluable at Week 52 Visit. 5 patients achieved CHAQ response (2 from etanercept group, 2 from secukinumab low dose group and 1 from placebo - secukinumab low dose)

The CHAQ questionnaire is only done for children who in addition to psoriasis are also suffering from psoriatic arthritis. The questionnaire is completed by parent or legal guardian. It consists of multiple choice items concerning difficulty in performing eight common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and other "activities". The person completing the questionnaire chooses from four response categories, ranging from 'without any difficulty' to 'unable to do'. Additionally two visual analog scales (overall well-being and pain of patient) must be performed.

Outcome measures

Measure	AIN457 Low Dose n=4 Participants Patients received secukinumab 75mg (if weighing \< 50kg) or 150 mg (if weighing \>=50 kg) at each dosing	AIN457 High Dose n=1 Participants Patients received secukinumab 75mg (if weighing \< 25kg) or 150 mg (if weighing 25 to \< 50kg ) or 300 mg (if weighing \>=50 kg) at each dosing	Placebo n=2 Participants Patients received matching placebo to secukinumab at each dosing	Etanercept n=1 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)	Etanercept n=3 Participants Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg)
Number and Percentage of Participants With Clinically Important Reduction in Disability as Evaluated by CHAQ Questionnaire Over Time at Week 52	2 Participants	0 Participants	1 Participants	0 Participants	2 Participants

Adverse Events

Any AIN457 Low Dose

Serious events: 7 serious events

Other events: 48 other events

Deaths: 0 deaths

Any AIN457 High Dose

Serious events: 8 serious events

Other events: 50 other events

Deaths: 0 deaths

Any AIN457 Dose

Serious events: 15 serious events

Other events: 98 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 19 other events

Deaths: 0 deaths

Etanercept

Serious events: 6 serious events

Other events: 30 other events

Deaths: 0 deaths

Serious adverse events

Measure	Any AIN457 Low Dose n=56 participants at risk Includes patients from the AIN457 Low Dose and from the Placebo-AIN457 Low Dose groups. AEs were collected for up to 252 weeks.	Any AIN457 High Dose n=58 participants at risk Includes patients from the AIN457 High Dose and from the Placebo-AIN457 High Dose groups. AEs were collected for up to 252 weeks.	Any AIN457 Dose n=114 participants at risk Any AIN457 dose. AEs were collected for up to 252 weeks.	Placebo n=41 participants at risk Patients received matching placebo to secukinumab at each dosing. AEs were collected for up to 28 weeks (12 weeks if participant switched to AIN457 at week 12).	Etanercept n=41 participants at risk Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg). AEs were collected for up to 68 weeks.
Blood and lymphatic system disorders Lymphadenopathy	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Abdominal hernia	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Abdominal pain	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Autoimmune pancreatitis	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Gastrointestinal toxicity	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
General disorders Non-cardiac chest pain	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Hepatobiliary disorders Gallbladder polyp	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Bronchitis	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Cellulitis	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Enterocolitis bacterial	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Infectious pleural effusion	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Lung abscess	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Pilonidal disease	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Pneumonia	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Toxic shock syndrome	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Injury, poisoning and procedural complications Clavicle fracture	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Injury, poisoning and procedural complications Concussion	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Injury, poisoning and procedural complications Contusion	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Investigations Alanine aminotransferase increased	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Metabolism and nutrition disorders Lactose intolerance	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Musculoskeletal and connective tissue disorders Arthritis reactive	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Musculoskeletal and connective tissue disorders Psoriatic arthropathy	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Nervous system disorders Syncope	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Pregnancy, puerperium and perinatal conditions Ectopic pregnancy	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Psychiatric disorders Major depression	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Psychiatric disorders Suicidal ideation	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Reproductive system and breast disorders Testicular torsion	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Vascular disorders Thrombophlebitis	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Vascular disorders Venous thrombosis limb	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.88% 1/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.

Other adverse events

Measure	Any AIN457 Low Dose n=56 participants at risk Includes patients from the AIN457 Low Dose and from the Placebo-AIN457 Low Dose groups. AEs were collected for up to 252 weeks.	Any AIN457 High Dose n=58 participants at risk Includes patients from the AIN457 High Dose and from the Placebo-AIN457 High Dose groups. AEs were collected for up to 252 weeks.	Any AIN457 Dose n=114 participants at risk Any AIN457 dose. AEs were collected for up to 252 weeks.	Placebo n=41 participants at risk Patients received matching placebo to secukinumab at each dosing. AEs were collected for up to 28 weeks (12 weeks if participant switched to AIN457 at week 12).	Etanercept n=41 participants at risk Patients received weekly open label etanercept 0.8 mg/kg of body weight (up to a maximum of 50 mg). AEs were collected for up to 68 weeks.
Blood and lymphatic system disorders Eosinophilia	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.6% 3/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Blood and lymphatic system disorders Neutropenia	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Abdominal pain	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	10.3% 6/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.8% 10/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	12.2% 5/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Abdominal pain upper	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.9% 9/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Dental caries	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Diarrhoea	12.5% 7/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	12.1% 7/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	12.3% 14/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Nausea	3.6% 2/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.4% 2/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Toothache	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.4% 5/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Gastrointestinal disorders Vomiting	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
General disorders Asthenia	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
General disorders Fatigue	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
General disorders Pyrexia	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	10.3% 6/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.8% 10/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Bronchitis	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	10.3% 6/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.9% 9/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations COVID-19	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.9% 9/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Conjunctivitis	3.6% 2/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.1% 7/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Folliculitis	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.1% 7/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Gastroenteritis	8.9% 5/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.0% 8/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Gastroenteritis viral	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Gastrointestinal infection	3.6% 2/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Impetigo	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.6% 3/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Influenza	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Nasopharyngitis	30.4% 17/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	43.1% 25/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	36.8% 42/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	26.8% 11/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Oral herpes	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.4% 2/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.4% 5/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Paronychia	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Pharyngitis	16.1% 9/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	13.8% 8/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	14.9% 17/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Pharyngotonsillitis	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.4% 5/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Respiratory tract infection	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.1% 7/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Rhinitis	8.9% 5/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	12.1% 7/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	10.5% 12/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Sinusitis	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.4% 2/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Tonsillitis	19.6% 11/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	12.1% 7/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	15.8% 18/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Upper respiratory tract infection	12.5% 7/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.8% 10/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.3% 3/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Urinary tract infection	8.9% 5/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.4% 2/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.1% 7/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Infections and infestations Viral upper respiratory tract infection	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.1% 7/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Investigations Aspartate aminotransferase increased	3.6% 2/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Investigations Glomerular filtration rate decreased	12.5% 7/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.6% 11/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Musculoskeletal and connective tissue disorders Arthralgia	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.9% 9/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Nervous system disorders Headache	19.6% 11/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	19.0% 11/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	19.3% 22/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Reproductive system and breast disorders Dysmenorrhoea	1.8% 1/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.4% 5/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Reproductive system and breast disorders Menstruation irregular	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.6% 3/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Respiratory, thoracic and mediastinal disorders Cough	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	15.5% 9/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	11.4% 13/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.2% 3/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.6% 3/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Respiratory, thoracic and mediastinal disorders Nasal congestion	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	7.1% 4/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	10.3% 6/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.8% 10/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Acne	14.3% 8/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	11.4% 13/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Eczema	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.0% 8/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Intertrigo	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	3.5% 4/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Pruritus	5.4% 3/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	8.6% 5/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.0% 8/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	4.9% 2/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Psoriasis	12.5% 7/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	1.7% 1/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	7.0% 8/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	9.8% 4/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	3.6% 2/56 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	6.9% 4/58 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	5.3% 6/114 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	0.00% 0/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.	2.4% 1/41 • Adverse Events were collected from first dose of study treatment until last dose of study treatment plus 16 weeks. In total 252 weeks for AIN457 arms and 68 weeks for Etanercept. Placebo PASI-75 responders at week 12 moved into the 16 weeks post-treatment follow-up. AEs were collected for 28 weeks. Placebo PASI-75 non-responders at week 12 switched to active AIN457 dose groups. AEs were collected for 12 weeks under Placebo and up to 240 weeks under AIN457 arms. Adverse Events are reported according to the actual treatment received at the onset of the AE.

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 862-778-8300

Email: Novartis.email@novartis.com

Results disclosure agreements

• Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.
• Publication restrictions are in place

Restriction type: OTHER